PapersFlow Research Brief
Histiocytic Disorders and Treatments
Research Guide
What is Histiocytic Disorders and Treatments?
Histiocytic disorders are rare conditions characterized by the accumulation of macrophage, dendritic cell, or monocyte-derived cells in various tissues and organs, with treatments focusing on classification, diagnosis, BRAF mutation-targeted therapies, immunohistochemical methods, and clinical management guidelines.
Histiocytic disorders encompass over 100 subtypes affecting children and adults, including Langerhans Cell Histiocytosis and Erdheim-Chester Disease, with 27,131 papers published on their classification, diagnosis, and treatment. Emile et al. (2016) in "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages" revised the categorization of these macrophage-dendritic cell lineage disorders based on clinical, pathologic, and molecular features. Khoury et al. (2022) in "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms" updated the WHO classification for myeloid and histiocytic/dendritic neoplasms.
Topic Hierarchy
Research Sub-Topics
Langerhans Cell Histiocytosis Pathogenesis
Researchers investigate clonal proliferation, immune dysregulation, and MAPK/ERK pathway activation in LCH lesions. Studies integrate single-cell RNA-seq with functional assays to define lesional heterogeneity.
BRAF Mutations in Histiocytic Neoplasms
This sub-topic profiles BRAF V600E prevalence across LCH, ECD, and RDD using NGS and IHC. Research evaluates mutation-functional correlations and co-occurring genomic alterations.
Erdheim-Chester Disease Clinical Management
Studies develop consensus guidelines for ECD diagnosis, multisystem staging, and therapy sequencing including vemurafenib and infliximab. Long-term outcome analyses address cardiovascular and CNS complications.
Immunohistochemical Classification of Histiocytoses
Researchers validate marker panels (CD1a, langerin, CD68, factor XIIIa) for lineage assignment per WHO 2016/2022 classifications. Algorithm development aids distinction of LCH, ECD, and Rosai-Dorfman.
Targeted Therapies for Multisystem Histiocytosis
Clinical trials evaluate BRAF/MEK inhibitors, cladribine, and cytarabine for high-risk LCH/ECD with vital organ involvement. Pharmacodynamic studies correlate response with pathway inhibition.
Why It Matters
Histiocytic disorders impact clinical management through precise classification enabling targeted therapies, as seen in BRAF mutation analysis for Langerhans Cell Histiocytosis and Erdheim-Chester Disease. Emile et al. (2016) in "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages" (1505 citations) established a framework linking histiocytoses to macrophage-dendritic cell lineages, guiding diagnosis for over 100 subtypes with varied presentations from single-system to multisystem involvement. Khoury et al. (2022) in "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms" (3500 citations) provides consensus guidelines for immunohistochemical approaches and therapy intensification in multisystem cases. Sundström and Nilsson (1976) in "Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)" (2424 citations) developed the U-937 cell line, aiding pathogenesis studies and drug testing for histiocytic lymphomas.
Reading Guide
Where to Start
"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages" by Emile et al. (2016), as it provides foundational categorization of over 100 histiocytosis subtypes integrating clinical and molecular data for initial understanding.
Key Papers Explained
Emile et al. (2016) in "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages" establishes the macrophage-dendritic cell lineage framework, which Khoury et al. (2022) in "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms" refines with updated WHO haematolymphoid tumour guidelines. Sundström and Nilsson (1976) in "Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)" complements these by offering an experimental model matching tumor morphology for pathogenesis studies.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current classification efforts build on Khoury et al. (2022) WHO updates, focusing on molecular characterization of dendritic cell neoplasms. No recent preprints or news available, so frontiers emphasize consensus clinical management for BRAF-mutated cases and multisystem therapy intensification from established guidelines.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The 5th edition of the World Health Organization Classificatio... | 2022 | Leukemia | 3.5K | ✓ |
| 2 | Chemotherapy drugs induce pyroptosis through caspase-3 cleavag... | 2017 | Nature | 3.0K | ✕ |
| 3 | Oral and maxillofacial pathology | 1996 | Journal of Oral and Ma... | 3.0K | ✕ |
| 4 | Establishment and characterization of a human histiocytic lymp... | 1976 | International Journal ... | 2.4K | ✕ |
| 5 | Kaposi's sarcoma-associated herpesvirus-like DNA sequences in ... | 1995 | Blood | 2.2K | ✓ |
| 6 | The Tuberous Sclerosis Complex | 2006 | New England Journal of... | 1.8K | ✕ |
| 7 | Identification and characterization of the tuberous sclerosis ... | 1993 | Cell | 1.7K | ✕ |
| 8 | Clinical Effect of Point Mutations in Myelodysplastic Syndromes | 2011 | New England Journal of... | 1.6K | ✕ |
| 9 | Revised classification of histiocytoses and neoplasms of the m... | 2016 | Blood | 1.5K | ✓ |
| 10 | Pemigatinib for previously treated, locally advanced or metast... | 2020 | The Lancet Oncology | 1.5K | ✓ |
Frequently Asked Questions
What is the revised classification of histiocytoses?
Emile et al. (2016) in "Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages" categorized histiocytoses as disorders of macrophage, dendritic cell, or monocyte-derived cells. This system recognizes over 100 subtypes with diverse clinical manifestations. The classification integrates pathologic and molecular data for improved diagnosis.
How does the WHO classify histiocytic/dendritic neoplasms?
Khoury et al. (2022) in "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms" outlines the latest myeloid and histiocytic/dendritic neoplasm categories. It incorporates immunohistochemical and molecular features like BRAF mutations. This edition supports standardized clinical management.
What role does the U-937 cell line play in histiocytic research?
Sundström and Nilsson (1976) in "Establishment and characterization of a human histiocytic lymphoma cell line (U‐937)" derived U-937 from a pleural effusion in generalized histiocytic lymphoma. The cell line mirrors tumor cell morphology. It serves as a model for pathogenesis and treatment studies.
What are key features of Langerhans Cell Histiocytosis?
Langerhans Cell Histiocytosis involves dendritic cell accumulation, often with BRAF mutations, as noted in the cluster description. Diagnosis uses immunohistochemical approaches. Treatments include therapy intensification for multisystem involvement.
How are BRAF mutations relevant to histiocytic disorders?
BRAF mutations drive pathogenesis in disorders like Langerhans Cell Histiocytosis and Erdheim-Chester Disease. Molecular characterization guides targeted therapies. Consensus guidelines recommend testing for clinical management.
Open Research Questions
- ? How do specific molecular drivers beyond BRAF mutations contribute to multisystem histiocytic disorders?
- ? What are optimal immunohistochemical markers for distinguishing histiocytic subtypes in challenging cases?
- ? Which therapy intensification strategies improve outcomes in high-risk Langerhans Cell Histiocytosis?
- ? How does the revised histiocytosis classification predict response to macrophage-targeted treatments?
Recent Trends
The field has advanced through Khoury et al. in "The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms" (3500 citations), updating histiocytic/dendritic neoplasm classifications post-Emile et al. (2016).
2022Total works remain at 27,131 with no reported 5-year growth.
No recent preprints or news indicate ongoing refinements in immunohistochemical and BRAF-focused approaches.
Research Histiocytic Disorders and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Histiocytic Disorders and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers